Interleukin-10 gene promoter polymorphism in English and Polish healthy controls. Polymerase chain reaction haplotyping using 3′ mismatches in forward and reverse primers

Koss, K; Fanning, G.C.; Ki, Welsh; Jewell, D P

doi:10.1038/sj.gene.6363669

Cited by 35 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The genotype and haplotype frequencies of IL10 polymorphisms in the control group were consistent with previously published studies from different regions in Saudi Arabian [1,11] and European populations [20]. Polymorphisms at -819 and -592 positions were found in complete linkage disequilibrium (LD) as it has been reported previously in different populations [12,15].…”

Section: Distribution Of Il10 Polymorphisms In a Saudi Populationsupporting

confidence: 89%

IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients

et al. 2015

View full text Add to dashboard Cite

Rheumatic heart disease (RHD) is an inflammatory disease that develops following streptococcal infections. IL10 helps to balance immune responses to pathogens. IL10 polymorphisms have been associated with RHD, although results remain inconclusive. Our aim was to investigate the association between IL10 polymorphisms and RHD in Saudi Arabian patients. IL10 promoter polymorphisms (-1082A/G, -829C/T, and -592C/A) were genotyped in 118 RHD patients and 200 matched controls using the TaqMan allelic discrimination assay. There was a significant difference in IL10-1082 genotype frequency between patients and controls (p = 0.01). -1082G allele carriage (GG+GA vs AA) and the (-1082, -819, -592) GCC haplotype carriage were associated with an increased risk of RHD (p = 0.004, OR 2.1, 95% CIs 1.7-3.4 and p = 0.004, OR 2, 95% CIs 1.3-3.4, respectively). The ACC haplotype was associated with a decrease in RHD risk (p = 0.015, OR 0.6, 95% CIs 0.4-0.9). IL10 promoter polymorphisms may play an important role in the development of RHD and provide an opportunity for therapeutic stratification.

show abstract

Section: Distribution Of Il10 Polymorphisms In a Saudi Populationsupporting

confidence: 89%

IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…28 The advantage of these strategies is that polymorphisms are physically linked through PCR and haplotypes can be determined unequivocally without the use of families.…”

Section: Typing Il-10 Polymorphismsmentioning

confidence: 99%

Cytokine (TNFα, LTα and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies

et al. 2000

Self Cite

View full text Add to dashboard Cite

The influence of biallelic polymorphisms in the tumour necrosis factor-alpha (TNF␣), lymphotoxin-alpha (LT␣) and interleukin-10 (IL-10) genes on stimulated TNF␣ and IL-10 production was studied in ulcerative colitis (UC) patients, Crohn's disease (CD) patients and in healthy controls. A polymerase chain reaction sequence-specific primer (PCR-SSP) system was developed to type nine biallelic polymorphisms, three in each of the TNF␣, LT␣ and IL-10 genes. Production of the TNF␣ and IL-10 was measured by ELISA in lipopolysaccharide (LPS) stimulated whole blood. Four haplotypes of the TNF␣ gene, three haplotypes of LT␣ and three haplotypes of IL-10 were identified. No significant differences in haplotype frequencies were found between patients and controls overall. On subgroup analysis however, haplotype TNF-2 was more frequent in women with extensive colitis compared to distal colitis (31% vs 12%; P = 0.028). This difference was even greater for the combined TNF-2-LT␣-2 haplotype (56% vs 21%; P = 0.0007). The TNF-2 and LT␣-2 haplotypes were associated with higher TNF␣ production in CD patients, and the TNF-4 haplotype was associated with lower TNF␣ production in UC patients. The A allele in the IL-10 promoter region at position −1082 was associated with decreased IL-10 production in CD patients and controls (P = 0.005, P = 0.015 respectively). These data provide evidence that the effect of TNF␣, LT␣ and IL-10 gene polymorphisms on cytokine production differ in CD, UC patients and controls. Genes and Immunity (2000) 1, 185-190.

show abstract

“…Polymerase chain reaction (PCR) with sequence-specific primers was used to define the IL-10 promoter SNPs at the Ϫ592, Ϫ819, and Ϫ1082 positions as reported. 23 These sites are also known as Ϫ627, Ϫ854, and Ϫ1117, respectively. 13 Two additional single nucleotide polymorphisms in the distal promoter region at positions Ϫ2763 and Ϫ3575 relative to the transcription start site were similarly typed using the following primers: IL-10-3575TF (sense primer specific for Ϫ3575T, 5Ј-gTA CAT CCC CCA CTg gAA AAA TT-3Ј), IL10-3575AF (sense primer specific for Ϫ3575A, 5Ј-gTA CAT CCC CCA CTg gAA AAA TA-3Ј), IL10-2763 CR (antisense primer specific for Ϫ2763C, 5Ј-CAC CAC gCC Cgg CTA Ag-3Ј), and IL10-2763AR (antisense primer specific for Ϫ2763A, 5Ј-gCA CCA CgC CCg gCT AAT-3Ј).…”

Section: Dna Extraction and Polymerase Chain Reaction-based Genotypinmentioning

confidence: 99%

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection

et al. 2001

View full text Add to dashboard Cite

Host genetic factors have been reported to influence the natural history of hepatitis C virus (HCV) infection. We examined whether variation in interleukin 10 (IL-10) and tumor necrosis factor ␣ (TNF-␣) genes would predict the likelihood of sustained response to antiviral therapy. Single nucleotide polymorphisms (SNPs) and microsatellites at two loci encoding the cytokines IL-10 and TNF-␣ were determined by polymerase chain reaction (PCR)-based techniques. Their relationship to the outcome of antiviral therapy for chronic HCV infection was studied in 49 white patients who had a virologically sustained response (SR) and in 55 white nonresponders (NR) to a combination of interferon alfa-2b and ribavirin (IFN ؉ R). Several IL-10 variants were more frequent among SRs compared with NRs. Carriage of the ؊592A or the ؊819T SNP was associated with SR (odds ratio [OR] ‫؍‬ 2.2; P ‫؍‬ .016). The ؊592A/A and the exclusively linked ؊819T/T genotypes were also associated with SR (OR ‫؍‬ 16.6; P ‫؍‬ .013 for either). The haplotype consisting of the 108-bp IL-10.R microsatellite and ؊3575T, ؊2763C, ؊1082A, ؊819T, ؊592A was also associated with SR (OR ‫؍‬ 2.65; P ‫؍‬ .01). Stratification for viral genotype, baseline viral RNA concentration, and histologic status identified homozygosity for the haplotype as the principal determinant: all 5 homozygous individuals achieved SR (OR crude ‫؍‬ 13.7; P ‫؍‬ .025; stratified ORs ‫؍‬ 1.9-7.0), whereas heterozygotes differed only slightly from wild-type carriers. In contrast, TNF alleles defined by promoter sequences ؊238G/A and ؊308G/A were approximately equally distributed among SR and NR. In conclusion, homozygosity for ؊592A, ؊819T or the extended haplotype (108bp) ؊ ( During the last decade, treatment for hepatitis C virus (HCV) infection has rapidly improved. Interferon alfa-2b in combination with ribavirin (IFN ϩ R) has become the standard regimen for HCV infection. Sustained response (SR) to IFN ϩ R, defined as undetectable HCV RNA at 6 months after discontinuation of therapy, is achievable in 30% to 60% of treated patients.

show abstract

Interleukin-10 gene promoter polymorphism in English and Polish healthy controls. Polymerase chain reaction haplotyping using 3′ mismatches in forward and reverse primers

Cited by 35 publications

References 7 publications

IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients

IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients

Cytokine (TNFα, LTα and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection

Contact Info

Product

Resources

About